Background and objective Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests.
Methods We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed.
Results In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment.
Conclusions The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials.
Clinical trial registration NCT01676077.
- muscle MRI
- muscular dystrophy
- outcome measures
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Statistics from Altmetric.com
Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by mutations in the DYSF gene.1 2 The absence or deficiency of dysferlin leads to muscle fibre necrosis and replacement by fat and fibrous tissue. The two most frequent presentations are limb girdle muscular dystrophy type 2B (LGMD-2B) and distal myopathy with calf involvement or Miyoshi myopathy (MM).3 Other phenotypes, such as distal myopathy with anterior tibial involvement, proximodistal weakness and pseudometabolic presentation, have also been described.4 Clinical symptoms usually start in young adulthood and are associated with highly elevated serum creatine kinase levels. The disease progresses invariably producing muscle weakness that markedly impairs daily life activities. Respiratory and cardiac involvement is uncommon in patients with dysferlinopathy.5
In recent years, muscle MRI protocols have been developed to assess disease progression in muscular dystrophies using sequences that are able to quantify the amount of fat replacement per muscle.6 7 Previous muscle MRI studies in dysferlinopathy showed initial involvement of the adductor magnus, semimembranosus and vastus lateralis muscles in the thigh and gastrocnemius medialis, soleus and tibialis anterior in the legs. The pattern of muscle involvement has not been described to vary between phenotypes, although these findings were reported in small cohorts.8–11
Natural history studies are essential to understand the progressive course of muscular dystrophies and to identify suitable outcome measures that can be used in future clinical trials. To address this gap, the Jain Foundation is funding The Clinical Outcome Study for Dysferlinopathy, a multicentre natural history study in a large cohort of patients (http://www.jain-foundation.org).12 Our aims in this paper are to identify the pattern of muscle pathology using MRI in a large cohort of patients with dysferlinopathy, to identify which muscles might be suitable to assess by quantitative MRI and study how MRI findings correlate with functional tests.
Study set-up and subjects
Two hundred and one patients with dysferlinopathy from 15 sites (Newcastle, Barcelona, Seville, Munich, Berlin, Padua, Marseille, Paris, Saint Louis, Columbus, Charlotte, Washington DC, Stanford, Tokyo and Sydney) were enrolled in the study. One hundred and eighty-two patients had an MRI scan (clinical and genetic details are described in online supplementary file 1). Inclusion criteria were ≥2 pathogenic mutations in DYSF or 1 pathogenic mutation plus either absent dysferlin expression on skeletal muscle immunoblot or ≤20% blood dysferlin monocyte expression. Truncating mutations and splice site mutations affecting the +1/–1 or +2/–2 positions were deemed pathogenic. Pathogenicity of other splice site mutations and missense mutations was defined according to the UMD Predictor (http://umd-predictor.eu).
Supplementary file 1
Demographic data were collected for ethnicity, gender, age, ambulatory status and disease duration. Patients were stratified according to the pattern of weakness at disease onset: (1) LGMD-2B, (2) MM, (3) proximodistal weakness, (4) other (pseudometabolic weakness). Those patients with no weakness at baseline examination but hyperCKemia were considered as (5) asymptomatic hyperCKemia. Disease duration was based on the time from onset of muscle weakness in symptomatic patients and time from first abnormal blood analysis result in patients with isolated hyperCKemia.
Functional status and physiotherapy assessment
Ambulation status was determined by the ability to walk 10 m with shoes and usual walking aids or orthotics. Physiotherapists assessed muscle strength in upper and lower limbs by manual muscle testing (MMT) using an Medical Research Council 11-point scale (0=no movement, 1, 2, 3–, 3, 3+, 4–, 4, 4+, 5–, 5=no weakness). A dysferlinopathy-adapted 22-item scale based on the original 17-item North Star Ambulatory Assessment (NSAA) scale used in Duchenne muscular dystrophy and the Motor Function Measure were used to assess motor performance.12 13 Timed tests (6 min walk test, rise from floor, 10 m walk/run, time to climb and descend four steps and timed up and go tests) were performed in ambulant patients. The Brooke scale was performed to evaluate upper limb functional status and the ACTIVLIM as a patient-reported outcome measure.14 15
Muscle MRI: acquisition
One hundred and eighty-two patients underwent a baseline muscle MRI scan, of which 84 patients had whole body and 98 patients lower limb scans. The core protocol consisted of T1-weighted, Dixon, B1 map and T2-weighted sequences. Here, we report the findings using anatomical T1-weighted sequences. The manufacturer, models and axial T1-weighted parameters are detailed in online supplementary file 2. The quality of the MRI studies was analysed by the study radiologists.
Supplementary file 2
Muscle MRI: Semiquantitative assessment
A blinded neurologist (RF-T) and radiologist (JL), both with experience in muscle MRI in neuromuscular disorders, independently evaluated axial T1-weighted sequences with the semiquantitative Mercuri visual scale, modified by Fischer, described in online supplementary file 2.16 The observers agreed on the scoring of 96% of muscles. Inter-rater agreement kappa was 0.93 (95% CI 0.91 to 0.96). For the remaining 4%, observers reviewed the muscles together and agreed a final score.
We divided the cohort into two groups depending on mutation type: (1) patients in whom absent dysferlin expression was predicted (harbouring homozygous or compound heterozygous truncating mutations) and (2) patients in whom reduced dysferlin expression was predicted (two missense mutations or one missense mutation and one truncating mutation). We compared median value of muscle fatty replacement between groups using the Wilcoxon-Mann-Whitney test.
We used the Shapiro-Wilk test to confirm that none of our variables were normally distributed. As such, non-parametric statistic tests were used for the analysis.
The Mann-Whitney U test was used to compare quantitative variables and the χ² test to compare qualitative variables. Due to the high number of comparisons studied, Bonferroni correction was used as posthoc analysis. To investigate correlations between muscle function tests and MRI findings, Spearman’s rank correlation was used (coefficient reported as ρ). The correlation was considered significant if p value was less than 0.05 and ρ was 0.6 or higher. Hierarchical analysis and graphical representation as a heatmap was performed using R software, V.3.1.3. Statistical analyses were performed using IBM SPSS Statistics, V.21 (IBM, Armonk, New York, USA).
Standard protocol approvals, registrations and patient consents
All participants provided informed consent. The study was approved by ethical review boards at each centre and registered at ClinicalTrials.gov (NCT01676077).
We included 182 patients (91 women, mean age at MRI 38±12.6 years) from whom we have obtained muscle MRI scans. Demographic, clinical and genetic data are summarised in online supplementary file 3.
Supplementary file 3
Muscle MRI involvement: general features
Signal abnormalities in T1-weighted images were detected in all but one patient (181 out of 182 patients). Asymmetric involvement, judged as a score difference of at least 2 points in at least one muscle, was found in 77 patients (41.8%) although in 51/77 patients the asymmetry was found in one muscle only. Asymmetry in two or more muscles was found in 26/77 patients. Muscles that had asymmetric involvement were variable.
Cranial involvement was analysed in 73 patients and fatty replacement was detected in 25 (34.2%). The tongue (34.2%) and the cervical paraspinal muscles (24.6%) were most commonly involved (figure 1A–D). In contrast, temporalis, masseter and sternocleidomastoideus muscles were least commonly affected (only in 1, 2 and 3 patients, respectively). The degree of fat replacement of the cervical paraspinal and sternocleidomastoideus muscles had a statistically significant correlation with item 1 ‘lifts head from supine’, from the NSAA-a, although the correlation coefficient was poor (ρ=0.46) (table 1).
Arm involvement was analysed in 35 patients. Hierarchical analysis identified two more commonly and severely involved muscles (online supplementary figure 1A): the biceps brachii (57.1%) and the anterior muscles of the forearm (53.8%). Commonly observed patterns included:
Supplementary file 4
Scapular involvement was analysed in 78 patients. Hierarchical analysis identified four muscles as more commonly and severely involved (figure 2): the subscapularis (80.8%), latissimus dorsi (75.3%), infraspinatus (73.8%) and supraspinatus (72.8%).
Commonly observed patterns included:
Trunk and pelvic muscles
Trunk and pelvic involvement was analysed in 89 patients. Hierarchical analysis identified six more commonly and more severely involved muscles (online supplementary figure 2): the tensor fascia latae (95%), gluteus minimus (90.8%), obturator externus (86%), iliocostalis (93.1%), longissimus (86.2%) and multifidus (88.5%).
Supplementary file 5
Commonly observed patterns included:
Thigh involvement was analysed in 182 patients. Hierarchical analysis identified four muscles that were more commonly and more severely involved (figure 3): the semimembranosus (95.4%), semitendinosus (90.2%), biceps femoris long head (93.5%) and adductor magnus (94.1%).
Commonly observed patterns included:
Lower leg muscles
Lower leg involvement was analysed in 182 patients. Hierarchical analysis identified three more commonly and more severely involved muscles (figure 4C): the soleus (99.45%), gastrocnemius medialis (99.45%) and the gastrocnemius lateralis (94.7%).
Commonly observed patterns included:
Influence of demographic and clinical features on muscle involvement
There were gender differences in the degree of muscle fatty involvement in some muscles. The rectus abdominis, rectus femoris, vastus intermedius, vastus lateralis, vastus medialis, peroneus longus, peroneus brevis, gastrocnemius lateralis, gastrocnemius medialis and soleus were more severely involved in women (Mann Whitney U test, p<0.05). Ethnicity did not appear to influence the degree of involvement. Neither the type of mutation nor the phenotype at onset correlated with the pattern or severity of the fat replacement on MRI.
Influence of disease duration on the degree of muscle pathology: a natural history approach
Disease duration (defined here as time since onset of muscle weakness) correlated with the degree of fat replacement in all anatomical regions (Spearman’s test, p<0.0001). To investigate the sequence of muscle involvement as the disease progressed, we classified the patients into six groups depending on the time to MRI from onset and calculated the median value of fat replacement of muscle tissue. The heatmaps obtained revealed a pattern of disease progression (figure 5). The muscles involved in the earliest stages of the disease were predominantly in the lower limbs, pelvis or trunk, although the subscapularis and the latissimus dorsi could also be involved early (figure 5). The rate at which fatty replacement progressed varied between muscles, for example, the soleus, gastrocnemius medialis and semimembranosus were usually completely involved after 10 years, while the adductor magnus or vastus lateralis were only completely involved when disease duration approached 25 years.
Correlation between functional tests and the muscle Mercuri score
The degree of fatty replacement on semiquantitative muscle MRI was correlated with the Brooke scale for the upper limbs, the 6 min walking test (6MWT) for the lower limbs and the NSAA, MMT and timed tests (table 1).
For the scapular muscles, we classified the patients into five groups according to the Brooke scale (the two least able scores were grouped together and indicated by the number 5) and calculated the median value of fat per muscle in every group of patients. The heatmap obtained (online supplementary figure 3) showed that the subscapularis, latissimus dorsi, infraspinatus and supraspinatus were involved in all patients, even if they were in the most functional group (ie, score of 1), while the levator scapulae or rhomboideus were only mildly involved, even in the least able patients (score 4 and 5).
Supplementary file 6
For the lower limbs, we classified patients into groups depending on distance covered in the 6MWT and calculated the median value of fat replacement for each muscle (figure 6). Using this approach, we suggest which muscles would be useful to follow longitudinally with muscle MRI according to the result of the 6MWT. For example, in the case of patients walking 600–700 m, the soleus, gastrocnemius medialis and the peroneus group were already involved, though to a mild degree. In contrast, these four muscles were completely transformed in patients walking 300–400 m and would therefore not be suitable for follow-up once function has decreased to this level. At this point, the graphic shows that the tibialis anterior, vastus intermedius or even the vastus medialis would be more useful for follow-up. In non-ambulant patients, the muscles useful for follow-up included the gracilis, the gluteus medius or the piriformis.
We have characterised muscle involvement on MRI in a large and clinically heterogeneous cohort of patients with dysferlinopathy. This large cross-sectional cohort has permitted better characterisation of the pattern of muscle involvement in dysferlinopathy and improved our understanding of disease progression. This information will support both diagnostics and clinical trial development.
We have defined a characteristic pattern of muscle involvement for dysferlinopathy, independent of the clinical phenotype. An early combination of fat replacement in distal posterior muscles of the lower limbs (gastrocnemius medialis and soleus) together with involvement of posterior muscles of the thighs (semimembranosus, semitendinosus, adductor major), pelvic muscles (tensor fascia latae and obturator externus), paraspinal muscles (multifidus, iliocostalis) and the scapular muscles (subscapularis and latissimus dorsi) can be helpful for differential diagnosis of patients with a muscle dystrophy and lead to an early diagnosis of dysferlinopathy. Moreover, some muscles are not involved until very late in the disease such as the levator scapulae, the rhomboideus the posterior muscles of the forearms, the gluteus maximus and medius muscles and the gracilis. This pattern of muscle involvement and sparing could be helpful for differential diagnosis by MRI in severely affected patients, in whom obtaining a muscle biopsy may be challenging.
We confirmed that there are no differences in the pattern of muscle involvement between patients with LGMD-2B, MM or other phenotypic presentations.9–11 This suggests that these subtypes of dysferlinopathy are not truly different and that a unifying pathophysiology is likely, similar to findings in other muscle diseases, such as the laminopathies, where different mutations result in similar patterns of selective muscle pathology.17 Extensive MRI investigations, rather than clinical descriptions, are therefore more likely to be helpful in understanding the pathophysiology of disease or the role of genetic modifiers. As previously mentioned, some muscles were more involved in women than men. Although we do not have a clear explanation to explain this issue, it is well known that testosterone and estrogens influence skeletal muscle homeostasis and metabolism and probably have an effect on muscle wasting in muscle dystrophies.18 Exercise has been shown to be important for muscle size and metabolism, which may be a factor rather than gender here.
The pattern of muscle involvement reported here can be considered characteristic for dysferlinopathy and contributes to differential diagnosis between other muscle diseases with limb girdle weakness. Patients with Becker muscular dystrophy tend to have early fatty replacement of the glutei medius and maximus while in contrast the adductor longus tends to be preserved until later stages.18 19 Muscle MRI scans of patients with LGMD-1B show no involvement of the vasti until later stages although the rectus femoris tends not to be affected and is often hypertrophic.17 20 Patients with LGMD-2A tend to have more severe involvement of the glutei and the vasti are less involved than the posterior muscles of the thighs.21 22 This pattern is similar in patients with LGMD-2I.23 Patients with sarcoglycanopathy, in whom there is usually no involvement of muscles of the lower legs before loss of ambulation, are easy to distinguish.24 Patients with adult-onset Pompe, which presents frequently with limb girdle weakness, have a muscle MRI pattern characterised by early involvement of axial, abdominal, gluteal and posterior thigh muscles, with the muscles of the lower legs not commonly involved.25 26 Patients with mutation in ANO5 (LGMD-2L) have a similar pattern of muscle involvement compared with patients with dysferlinopathy, with predominant involvement of the posterior muscles of the lower legs associated with involvement of posterior and anterior muscles of the thighs without involvement of the glutei.27–29 However, some differences can be found: the gluteus minimus and medius seem more commonly involved in LGMD-2L than in LGMD-2B and asymmetric involvement is more pronounced in LGMD-2L than dysferlinopathy.26 28
Previous similar radiological studies in dysferlinopathy have been performed in lower limbs only and involved small cohorts.9–11 30 Although these studies describe some of the features found here, we have expanded the range of patients analysed, using data from patients of different ethnic origins at many different stages of the disease.
We presented the pathology scores from T1-weighted images as heatmaps, as has been recently described for other muscle disorders.31 32 This is a new approach to display large amount of data, which simplifies the analysis of several variables. Following this method, we identified a clear correlation between disease duration and the degree of muscle involvement. This analysis raises interesting questions about factors affecting the rate of muscle degeneration. We showed that some muscles were involved early, while others were not involved until much later. In addition, while a group of muscles could become involved at the same time, the progression of fat replacement between muscles in a group could also vary. For example, in most patients, the gastrocnemius medialis becomes completely replaced by fat in less than 10 years from symptom onset, while the biceps femoris long head, while also involved in the first 10 years, remains minimally affected for longer. It is tempting to hypothesise that muscles with a slower progression could express proteins that protect them from rapid degeneration. Despite previous attempts to investigate this in dysferlinopathy, it is still not clear why muscle degeneration shows a different rate of progression.33 The clear understanding of the pattern of severely involved and spared muscles demonstrated here should allow for more focused investigations in the future.
T1-weighted muscle MRI has traditionally been used for differential diagnosis of muscle diseases or to select a suitable muscle to biopsy.34 35 As the development of novel therapeutics for many muscular dystrophies progresses, there is a growing need for reliable biomarkers to follow-up patients.36 We have shown that muscle MRI findings correlate with the results of most functional tests that may be included in clinical trials (table 1), adding weight to its use as a biomarker. However, as dysferlinopathy is a slowly progressive disorder, changes from 1 year to the next are probably not significant enough to be detectable using semiquantitative T1w imaging. Quantitative sequences such as 3-point Dixon or T2-mapping should be more useful for patient follow-up in short-term longitudinal studies.37–39 However, the present study can inform longitudinal quantitative MRI studies regards which muscles to monitor at different stages of disease.
This work is the result of a large international collaboration between different clinical and radiological groups to harmonise MRI protocols. However, although the study includes a high number of patients with different phenotypes and different disease stages, it has some obvious limitations. First, not all patients were studied with whole body muscle MRI due to technical limitations in some centres. Second, the MRI systems used were different, which can include some variability in the data obtained. Third, there are no data regarding Short-TI Inversion Recovery (STIR) results, but T2 imaging has been carried out and scans are currently under analysis.
In summary, our study provides information about the distribution and degree of fat replacement of muscle tissue in the largest cohort of patients with dysferlinopathy analysed to date. The study has expanded the characterisation of patterns that can be found in patients with dysferlinopathy, regardless of their clinical phenotype. We have also shown a correlation between muscle pathology as detected by MRI with disease duration and the results of related functional tests, which will inform the design of future clinical trials.
This study has only been possible thanks to the international collaboration of several specialised centres promoted by the Jain Foundation. The Jain COS consortium would like to thank the study participants and their families for their invaluable contribution and would also like to acknowledge the ongoing support the Jain Foundation provides in the development, management and analysis of this study. The Jain Foundation, based in Seattle, USA, is entirely focused on LGMD2B/dysferlinopathy/Miyoshi Myopathy. The foundation does not solicit funding from patients, but instead funds research and clinical studies worldwide with the goal of finding treatments for dysferlinopathy. Please visit http://www.jain-foundation.org for more information about the foundation and if you are a patient suffering from dysferlinopathy, please consider enrolling into their interactive dysferlinopathy registry that seeks to build a strong, engaged and supportive community (email@example.com).
Contributors JD-M, RF-T, MJ, AM, AMB, PGC, ME, MJ: design of the study, acquisition and analysis of data, drafting the paper. JLLR, FES: design of the study, acquisition and analysis of data. LR, PM: design of the study, drafting the paper, obtaining funding for the project, coordination of the study. AC, TH, DW,LW, MS, RS, AR, NS, TT, BH , SRG, ST, EM, GF, DB, YLF, STF, HJO, SF, AP, AMS, HL,UG, SS, CTR, JWD, KJJ, DXB-G, ES-C, MH, AP, OS-K, MCW, CP, J-YH, TS, ST, MM-Y, EB,SS, LB, CS, EP, JRM: acquisition and analysis of data, drafting the paper. HH: coordination of the study, drafting the paper. KB, VS: design of the study, coordinating of the study, acquisition and analysis of data, drafting the paper.
Funding The estimated $4 million USD needed to fund this study is being provided by the Jain Foundation. The John Walton Centre Muscular Dystrophy Research Centre is part of the MRC Centre for Neuromuscular Diseases. (Grant number MR/K000608/1).
Competing interests None declared.
Patient consent Not required.
Ethics approval Newcastle and North Tyneside2.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Study data can be requested from the study steering group using the following email address. firstname.lastname@example.org.
Collaborators The Jain COS Consortium: Adrienne Arrieta: Data management and training; Jia Feng: Data management; Esther Hwang, Elaine Lee: Recruitment, development of assessment forms; Isabel Illa, Eduard Gallardo, Irene Pedrosa Hernández, Izaskun Belmonte Jimeno, Elke Maron, Juliana Prügel, Mohammed Sanjak, Linda P Lowes, Lindsay Alfano, Katherine Berry, Bernard Lapeyssonie, Attarian Shahram, Simone Thiele, Karen Bettinson, Robert Muni Lofra, Debra Galley, Chiara Calore, Teresa Gidaro, Laurent Servais, Aurélie Canal, Gwenn Ollivier, Valérie Decostre, Cyrille Theis, Julaine Florence, Catherine Siener, Jeanine Schierbecker, Bosco Méndez, Pilar Carbonell, Nieves Sanchez-Aguilar, Macarena Cabrera, Yolanda Morgado, Richard Gee, Nigel F Clarke, Sarah Sandaradura, Roula Ghaoui, Kayla Cornett, Clare Miller, Meghan Harman, Yoko Kobayashi, Hiroyuki Yajima, Chikako Sakamoto, Takayuki Tateishi, Ai Ashida, Takahiro Nakayama, Kazuhiko Segawa, Harumasa Nakamura, En Kimura, Brittney Drogo, Meganne E Leach: Site Investigators; Sachiko Ohtaguro: Study assistant; Jackie Sykes, Brent Yetter, Testot-Ferry Albane, Oumar Diabaté, Linda Schimmoeller, Jennifer Perez, Maki Ohhata, Makiko Endo, Allyn Toles: Study coordinators; Nora Brody: Investigator; Tina Duong, Kristy Rose: Site Investigator/Trainer; Elizabeth Harris, Dionne Moat: Clinical Investigators.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.